Print（PDF/495KB） Nov. 02, 2026 Corporate

Notice Regarding the Execution of Definitive Agreement for the Succession of the GMP-Compliant Cell Processing CDMO Business by S-RACMO

S-RACMO Co., Ltd. (Head Office: Suita, Osaka; President and CEO: Atsushi Tsuchida; “S-RACMO”), a joint venture between Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; “Sumitomo Pharma”) and Sumitomo Chemical Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director and President: Nobuaki Mito; “Sumitomo Chemical”), executed a Master Agreement with Takara Bio Inc. (Head Office: Kusatsu, Shiga; President and CEO: Tsuyoshi Miyamura; “Takara Bio”) on November 2, 2026, as the definitive agreement for S-RACMO’s succession of Takara Bio’s GMP-compliant cell processing CDMO business (the “Business Succession”). Please refer to the attached document for further details.

Sumitomo Pharma has positioned regenerative and cellular medicine as one of its medium- to long-term growth areas and considers the Business Succession an important initiative toward expanding its regenerative and cellular medicine business.

Through the Business Succession, S-RACMO will take over personnel, assets, contract projects, and other items, and will combine the technologies and know-how in cellular immunotherapies cultivated by Takara Bio with S-RACMO's experience in the manufacturing of regenerative medicine and cell therapy products, thereby strengthening its contract manufacturing capabilities and business foundation.

Going forward, Sumitomo Pharma will continue to collaborate with Sumitomo Chemical, RACTHERA Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and CEO: Atsushi Ikeda), and S-RACMO, aiming to drive the growth of its regenerative and cellular medicine business and provide patients with new treatment options by bringing together the technologies and expertise of each company.